EUVIMEDEUVIMED entdecken
Crossref

Determination of Zipalertinib Using LC‐ESI‐MS/MS and Application to Pharmacokinetic Study in Mice

Abhishek Dixit, Arunava Das iD

Biomedical Chromatography · 2025

DOI: 10.1002/bmc.70228 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biomedical Chromatography, 2025. Verfasst von Abhishek Dixit und 1 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Life Sciences, Mandsaur University, Mandsaur, Madhya Pradesh, India. Hauptthemen laut MEDLINE: Tandem Mass Spectrometry, Piperazines, Spectrometry, Mass, Electrospray Ionization. Die Arbeit nennt 27 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Zipalertinib is a novel, irreversible EGFR inhibitor for the treatment of non‐small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations. A new sensitive, specific and rapid LC‐ESI‐MS/MS method has been developed and validated to quantify zipalertinib in mouse and human dried blood spot (DBS) with filgotinib used as an internal standard (IS) in accordance with regulatory guidelines. Quantification of zipalertinib and IS were achieved by triple quad mass spectrometer operated under the multiple reaction‐monitoring mode (MRM) using positive ion scan mode and parent‐daughter mass to charge ion transition of m/z 397.2 → 326.0 and m/z 426.2 → 291.2, respectively. The linear response function of zipalertinib was determined in the concentration range from 0.741 to 1111 ng/mL ( r > 0.990). No matrix effect and carry over were observed. Hematocrit did not influence DBS zipalertinib concentrations. Zipalertinib demonstrated stability under various storage conditions. This method was successfully used to study the in vitro metabolic profiles and in vivo pharmacokinetics of zipalertinib in mice. An excellent correlation was observed between DBS and plasma concentrations, indicating DBS can be used as an alternative for plasma for pharmacokinetic analysis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Tandem Mass SpectrometryPiperazinesSpectrometry, Mass, Electrospray IonizationAnimalsMiceChromatography, LiquidReproducibility of ResultsLinear ModelsHumansLimit of DetectionMaleSensitivity and SpecificityDried Blood Spot TestingDrug Stability

Stichwörter der Autor:innen

DBSLC‐MS/MSmethod validationmouse plasmapharmacokineticszipalertinib

Substanzen

Piperazines

Autor:innen und Institutionen

  • Faculty of Life Sciences, Mandsaur University, Mandsaur, Madhya Pradesh, India.

ORCID-Profile: Arunava Das

Zitieren

APA

Dixit, A., & Das, A. (2025). Determination of Zipalertinib Using LC‐ESI‐MS/MS and Application to Pharmacokinetic Study in Mice. Biomedical Chromatography. https://doi.org/10.1002/bmc.70228

Vancouver

Dixit A, Das A. Determination of Zipalertinib Using LC‐ESI‐MS/MS and Application to Pharmacokinetic Study in Mice. Biomedical Chromatography. 2025. doi:10.1002/bmc.70228

BibTeX
@article{Dixit2025,
  author = {Dixit, Abhishek and Das, Arunava},
  title = {Determination of Zipalertinib Using LC‐ESI‐MS/MS and Application to Pharmacokinetic Study in Mice},
  journal = {Biomedical Chromatography},
  year = {2025},
  doi = {10.1002/bmc.70228}
}
Kostenlos starten →